Aviva PLC Biomarin Pharmaceutical Inc Transaction History

Aviva PLC

$36.8 Billion
Q3 2024

A detailed history of Aviva PLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Aviva PLC holds 7,112 shares of BMRN stock, worth $471,312. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,112

Previous 12,621 43.65%

Holding current value

$471,312

Previous $1.04 Million 51.97%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$69.02 - $93.84 $380,231 - $516,964	-5,509 Reduced 43.65%	7,112 $499,000
Q2 2024 Aug 02, 2024	BUY	$74.43 - $92.22 $405,792 - $502,783	5,452 Added 76.05%	12,621 $1.04 Million
Q1 2024 May 14, 2024	BUY	$83.81 - $99.0 $15,169 - $17,919	181 Added 2.59%	7,169 $626,000
Q4 2023 Feb 09, 2024	SELL	$76.22 - $98.51 $2,515 - $3,250	-33 Reduced 0.47%	6,988 $673,000
Q3 2023 Nov 13, 2023	SELL	$85.07 - $94.48 $1.68 Million - $1.87 Million	-19,779 Reduced 73.8%	7,021 $621,000
Q2 2023 Aug 10, 2023	BUY	$86.68 - $100.3 $1.52 Million - $1.76 Million	17,506 Added 188.36%	26,800 $2.32 Million
Q1 2023 May 12, 2023	SELL	$87.74 - $117.27 $4.89 Million - $6.54 Million	-55,771 Reduced 85.72%	9,294 $903,000
Q4 2022 Feb 09, 2023	BUY	$80.93 - $108.63 $3.11 Million - $4.17 Million	38,415 Added 144.15%	65,065 $6.73 Million
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $673,712 - $794,908	-8,200 Reduced 23.53%	26,650 $2.26 Million
Q2 2022 Aug 04, 2022	SELL	$71.48 - $86.85 $84,560 - $102,743	-1,183 Reduced 3.28%	34,850 $2.89 Million
Q1 2022 May 13, 2022	SELL	$74.28 - $92.69 $1.37 Million - $1.71 Million	-18,491 Reduced 33.91%	36,033 $2.78 Million
Q4 2021 Feb 10, 2022	SELL	$71.72 - $91.47 $93,881 - $119,734	-1,309 Reduced 2.34%	54,524 $4.82 Million
Q3 2021 Nov 12, 2021	SELL	$74.77 - $85.47 $207,411 - $237,093	-2,774 Reduced 4.73%	55,833 $4.32 Million
Q2 2021 Aug 10, 2021	SELL	$75.51 - $84.79 $179,336 - $201,376	-2,375 Reduced 3.89%	58,607 $4.89 Million
Q1 2021 May 13, 2021	SELL	$74.73 - $90.69 $37,589 - $45,617	-503 Reduced 0.82%	60,982 $4.61 Million
Q4 2020 Feb 10, 2021	BUY	$72.61 - $90.2 $232,424 - $288,730	3,201 Added 5.49%	61,485 $5.39 Million
Q3 2020 Nov 12, 2020	SELL	$71.87 - $131.03 $1.45 Million - $2.64 Million	-20,155 Reduced 25.7%	58,284 $4.43 Million
Q2 2020 Aug 13, 2020	SELL	$79.55 - $124.22 $2.33 Million - $3.64 Million	-29,308 Reduced 27.2%	78,439 $9.68 Million
Q1 2020 May 14, 2020	BUY	$71.37 - $96.85 $1.49 Million - $2.02 Million	20,852 Added 24.0%	107,747 $9.11 Million
Q4 2019 Feb 10, 2020	BUY	$64.27 - $86.37 $1.52 Million - $2.04 Million	23,669 Added 37.44%	86,895 $7.35 Million
Q3 2019 Nov 12, 2019	SELL	$67.4 - $85.11 $139,450 - $176,092	-2,069 Reduced 3.17%	63,226 $4.26 Million
Q2 2019 Jul 30, 2019	SELL	$80.35 - $93.9 $110,240 - $128,830	-1,372 Reduced 2.06%	65,295 $5.59 Million
Q1 2019 May 14, 2019	BUY	$84.2 - $98.62 $37,637 - $44,083	447 Added 0.68%	66,667 $5.92 Million
Q4 2018 Feb 12, 2019	SELL	$80.14 - $106.07 $1.49 Million - $1.97 Million	-18,574 Reduced 21.9%	66,220 $5.64 Million
Q3 2018 Nov 13, 2018	SELL	$93.92 - $105.72 $283,544 - $319,168	-3,019 Reduced 3.44%	84,794 $8.22 Million
Q2 2018 Aug 01, 2018	SELL	$76.01 - $99.03 $98,128 - $127,847	-1,291 Reduced 1.45%	87,813 $8.27 Million
Q1 2018 May 14, 2018	SELL	$77.67 - $92.63 $632,311 - $754,100	-8,141 Reduced 8.37%	89,104 $7.22 Million
Q4 2017 Feb 13, 2018	SELL	$80.76 - $95.13 $935,604 - $1.1 Million	-11,585 Reduced 10.65%	97,245 $8.67 Million
Q3 2017 Nov 13, 2017	BUY	$80.6 - $94.95 $199,888 - $235,476	2,480 Added 2.33%	108,830 $10.1 Million
Q2 2017 Aug 07, 2017	BUY	N/A	106,350	106,350 $9.66 Million

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.3B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aviva PLC, based on Form 13F filings with the SEC.

News

Stay updated on Aviva PLC with notifications on news.

Account